Cancer invasion and metastasis occur in a complex three-dimensional environment, with reciprocal feedback from the surrounding host tissue and vasculature governing behavior. In this study, we used a novel intravital method that revealed spatiotemporal regulation of Src activity in response to the anti-invasive Src inhibitor dasatinib. A FLIM-FRET Src-biosensor was used to monitor drug targeting efficacy in a transgenic p53-mutant mouse model of pancreatic cancer. In contrast to conventional techniques, FLIM-FRET analysis allowed for accurate, time-dependent, live monitoring of drug efficacy and clearance in live tumors. In three-dimensional organotypic cultures, we demonstrated that a spatially distinct gradient of Src activity exists within invading tumor cells, governed by the depth of penetration into complex matrices. In parallel, this gradient was also found to exist within live tumors, where Src activity is enhanced at the invasive border relative to the tumor cortex. Upon treatment with dasatinib we observed a switch in activity at the invasive borders, correlating with impaired metastatic capacity in vivo. Src regulation was governed by the proximity of cells to the host vasculature, as cells distal to the vasculature were regulated differentially in response to drug treatment compared to cells proximal to the vasculature. Overall, our results in live tumors revealed that a threshold of drug penetrance exists in vivo and that this can be used to map areas of poor drug targeting efficiency within specific tumor microenvironments. We propose that employing FLIM-FRET in this capacity could provide a useful preclinical tool in animal models prior to clinical translation.
Introduction
Maximising the utility of preclinical disease models in drug discovery requires the development of new innovative approaches for the study of drug delivery at the molecular level in live tissue. Examining cancer behavior in an intact host setting allows us to understand, in a more physiological context, the aberrant regulation of critical events that drive tumor progression. Intravital imaging is providing new insights on how cells behave in a more native microenvironment, thereby improving our understanding of disease progression [1, 2] . In combination with adaptations of in vitro molecular techniques to three-dimensional model systems, intravital imaging is helping to bridge the gap in our understanding of key biological events that govern cancer progression and therapeutic response in vivo [2, 3, 4] .
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of human cancer, with 90% of patient deaths occurring within 1 year of diagnosis due to surgically unresectable, locally advanced or metastatic disease being present at the time of clinical diagnosis [5] . Systemic therapies are largely ineffective in inoperable disease, leading to an overall 5-year survival rate of less than 5% [6, 7] . In addition, the tumor microenvironment is characterized by poor vascularity and extensive deposition of ECM, limiting the accumulation and perfusion of drug delivery within the tumor tissue [8, 9, 10] . Consequently, the development of more effective strategies to efficiently target and treat pancreatic cancer is required.
Recently we have used a genetically engineered (Kras Pdx1-Cre (KPC)) mouse model of pancreatic cancer in which Cre-lox technology is used to target Kras G12D and mutant p53 R172H to the pancreas via the Pdx1 promoter [11] . This results in the formation of invasive and metastatic PDAC that recapitulates the pathology of human disease [12, 13] . Using this model, we previously demonstrated that introduction of a mutant p53 R172H allele, drives a metastatic program, over and above the tumor-promoting effects of p53 loss [14] . We and others have also shown that mutations in p53 provide a gain-of-function role that drives metastasis, via disruption of cell-cell and cell-matrix adhesion, leading to invasion and spread of disease [14] [15] [16] [17] [18] [19] [20] .
A number of new therapeutics have been developed to exploit the deregulation of non-receptor tyrosine kinases such as Src in cancer and are currently under clinical investigation [21] . Elevated expression and/or activity of Src has been shown to contribute to various types of invasive tumor cell behavior including evasion of apoptosis, enhancement of proliferation and the deregulation of cell-cell and cellmatrix adhesions, associated with numerous forms of cancer including pancreatic cancer [22] [23] [24] . In line with this, we recently demonstrated a correlation between Src up-regulation and activation with reduced survival in human pancreatic cancer, and
showed that the level of Src and phospho-Src are important indicators of vascular invasion, lymph node positivity and prognosis in human PDAC [25] . Importantly, we also established that the small molecule Src kinase inhibitor, dasatinib, which is currently being clinically evaluated in combination with chemotherapy in locally advanced PDAC [26] inhibited invasion of primary PDAC cells generated from this model, and significantly reduced the development of metastases by ~50% [25] .
As the current therapeutic failure of agents in the treatment of pancreatic cancer may arise from a potentially reversible impairment in drug delivery to the tumor [27] it remains to be determined whether improvements in drug targeting and effective delivery could enhance the encouraging anti-metastatic profile of dasatinib and improve survival in this aggressive disease [25] .
Here, we have adopted a fluorescence resonance energy transfer (FRET) biosensor, previously used to examine the dynamic regulation and activation state of were tail vein injected into mice 10 min prior to imaging (10 μl in 190 μl HBSS).
For control or drug treated tumor, at least 300 cells were measured. Columns, mean;
error bars represent ± SE, P value by unpaired student's t-test.
Frequency domain FLIM.
In vitro fluorescence Lifetime measurements were performed using a Lambert Instruments fluorescence attachment (LIFA) on a Nikon
Eclipse TE 2000-U microscope equipped with a 60x objective and a filter block consisting of a 436/20 excitation filter, a T455LP dichroic mirror, and a 480/40 emission filter. For more details, see supplementary information.
Organotypic invasion assay.
Organotypic asays were performed as described previously [36] . Briefly, ~7.5x10 4 /ml primary human fibroblasts were embedded in a three-dimensional matrix of rat tail collagen ȱ. Rat tail tendon collagen was prepared by extraction with 0.5 M acetic acid to a concentration of ~2 mg/ml. Detached, polymerized matrix (2.5 ml) in 35 mm petri dishes was allowed to contract for 6-8 days in complete media (DMEM, supplemented with 10% FCS, Invitrogen) until the fibroblasts had contracted the matrix to 1.5 cm diameter. Subsequently, 4x10 4 Src biosensor-expressing PDAC cells were plated on top of the matrix in complete media and allowed to grow to confluence for 4-5 days. The matrix was then mounted on a metal grid and raised to the air/liquid interface resulting in the matrix being fed from June 7, 2013; DOI: 10.1158/0008-5472.CAN-12-4545 below with complete media that was changed every 2 days. After 6-8 days invasion, the cultures were imaged as described or fixed using 4% paraformaldehyde and processed for hematoxylin and eosin (H&E) staining. For drug treatment, 100 nM of dasatinib (BMS) was added to the media below the matrix during the 6-8 day period as described. For cyclopamine treatment, 2.5-10 μM was added directly after matrix detachment prior to contraction [32, 40] . Representative images of at least 3 independent experiments are shown, total of 985 cells assessed by FLIM-FRET.
Columns, mean; error bars represent ± SE, P value by unpaired Student's t-test. Author Manuscript Published OnlineFirst on June 7, 2013; DOI: 10.1158/0008-5472. drug clearance in a time-dependent manner, we performed an in vitro washout experiment in which PDAC cells were subjected to 100 nM dasatinib for 30 mins, and subsequently monitored Src activity in response to dasatinib withdrawal using FLIM-FRET over 6 hrs. The efficacy of dasatinib treatment was demonstrated by a significant decrease in the fraction of Src-active cells upon dasatinib treatment (Fig2C, decreasing from 54.8 ± 3.7 % to 35.7 ± 6.9 %). Following washout, a rapid recovery in the fraction of Src-active cells was observed after 1hr, which peaked at 3hrs (P = 0.014) and subsequently returned towards control levels within 6 hrs (Fig2C). The capacity to track Src activity overtime in vitro prompted us to gauge whether we could use this approach to investigate temporal drug targeting and clearance under more functional and physiological conditions in live animal tumors.
Drug treatment in vitro
Monitoring drug targeting and clearance in a live microenvironment using FLIM-FRET. We have previously used multiphoton-based FLIM to quantify protein activity at depths of ~150 μm within solid tumor tissue, providing a powerful tool to directly examine cancer progression in situ [19] . This allowed us to readily investigate cells surrounded by ECM, stroma and vasculature in a live setting upon drug treatment. Here, we subcutaneously injected mice with primary PDAC cells, and once tumors were established, subjected these mice to daily oral gavage of 10 mg/kg of dasatinib for 3 days (Fig3A). Inactivation of Src activity was evident under these conditions, as previously described [19, 25, 29] . After the final administration of dasatinib, Src activity was subsequently monitored using FLIM-FRET at time points of 1-2 hrs; 4-6 hrs; 16 hrs and 24 hrs post-treatment (see imaging regimen Fig3A).
After the final dose of dasatinib, a rapid recovery of Src activity was observed, reaching a maximum at 16 hr post-drug treatment before returning to control levels 2013; DOI: 10.1158/0008-5472.CAN-12-4545 located in areas of poor drug exposure may recolonize or subsequently repopulate to form micro-metastases following treatment, it would be beneficial to identify regions of poor drug delivery within various solid tumor environments using FLIM-FRET.
Next, we determined whether single cell analysis of Src activity could be used to assess the targeting of dasatinib with respect to the host vasculature.
Mice bearing primary PDAC tumors were generated as before and treated with 10 mg/kg of dasatinib for 3 days ( 
Measuring the efficacy of combination therapy using FLIM-FRET in vivo.
Targeting the tumor architecture to favor drug penetration has recently been employed to improve drug delivery in pancreatic cancer [27] . In particular, the role that tumor- To assess whether cyclopamine treatment reduces ECM content [10] we initially subjected organotypic matrices to cyclopamine treatment during matrix formation. Treatment with cyclopamine led to a dose-dependent reduction in stromal fibroblast-driven collagen I contraction (Fig7A,B) . Moreover, the fibrillar and crosslinked collagen I content in organotypic matrices was significantly reduced as quantified by SHG imaging (as previously described [43] (Fig 7E,F) . (SEM), respectively P = 0.407). Importantly, the effect of cyclopamine + dasatinib at 100 μm from the vasculature was equivalent to cyclopamine alone at this distance (Fig 7G) . Indicating that we have reached the limitation of this combination therapy as no further improvement in drug efficacy at this distance can be achieved using this combination. As cyclopamine was shown to have no direct effect on Src activity in tumor cells alone (Fig 7E,F) Finally, the dynamic tumor analysis described here can be applied to other strategies aimed at altering drug delivery, such as approaches to enhance the vascular patency of blood vessels prior to treatment to increase perfusion within the tumor tissue [8, 9] . The transient normalization of tumor vessels in response to short-term anti-angiogenic agents has also been shown to temporarily enhance drug delivery to tumors [55] . There is therefore a clear limit to how much we can alter the ECM or blood supply, such that we do not compromise the integrity and structure of the 
